 |
Building a Forward Line of Defense
Securing Former Soviet Biological Weapons
Kenneth N. Luongo, Derek Averre, Raphael Della Ratta,
and Maurizio Martellini
Preventing a biological weapons attacklong a terrifying battlefield
danger and now a serious threat to civilian populations as wellis
a major contemporary global security priority. The anthrax attack
on the U.S. Congress, the discovery of ricin laboratories in France
and the United Kingdom, and the unearthing of documents detailing
pathogen production processes in al Qaeda hideouts indicate that terrorists
are willing to pursue both biological weapons development and use.
.
The rapid advances that have occurred in biotechnology, the small
footprint of many laboratories, and the difficulty in locating and
securing biological pathogen stockpiles further increase the already
difficult challenges of preventing the spread of biological weapons.
In addition, the recent discovery of nuclear procurement and technology
transfer networks in the Middle East, Asia, Africa, and Europe have
underscored the difficulty of comprehensively tracking illicit and
covert movements of weapons of mass destruction (WMD) and related
technology.
In the past few years, the United States has responded to the threat
from biological weapons by pouring more than $14 billion into attack
response preparedness and biodefense programs under the Department
of Homeland Security and other agencies. However, neither the United
States nor its key allies have taken the step of creating an effective
forward line of defense against bioterrorism by rapidly accounting
for and securing known stockpiles of pathogens on foreign shores.
Although a number of nations may possess suspected biological weapons
programs, this accelerated security effort should begin in Russia
and the former Soviet states. A vast complex of Soviet-era biological
research and development institutes still exists, questions remain
about the adequacy of the security of the pathogen collections at
a number of the facilities, and numerous scientists are threatened
with unemployment as a result of the downsizing of facilities and
the elimination of state subsidies.
Russia has renounced its offensive biological weapons capability,
but as a key partner in the fight against proliferation, it needs
to do more to secure its biological materials and technologies adequately
and to redirect former weapons scientists to peaceful activities.
These issues must transcend traditional arms control approaches and
are best addressed through the expansion of current U.S. and allied
programs aimed at reducing former Soviet stockpiles of nuclear, chemical,
and biological weapons.
The West has been engaged in these cooperative efforts with Russia
and the former Soviet states for more than a decade, and managing
biological threats has become an increasingly important priority.
Still, spending is paltry both in comparison to U.S. nuclear-related
foreign assistance and to U.S. domestic defenses against biological
weapons threats. The United States, which has led this effort, is
still spending less than $100 million annually (see
sidebar for details) under multiple programs. These efforts are
supplemented by another $25-30 million provided by Western-nation
contributions to science centers in Russia and Ukraine and another
half-million dollars in assistance coming directly from some European
nations to projects in Russia and the former Soviet states.
There are several reasons for this funding shortfall, including a
lack of prioritization and urgency in key Western governments. A crucial
sticking point, however, is the unwillingness of the Russian government
to permit Western access to several sensitive biological facilities
and the Kremlins reluctance to override an entrenched bureaucracy
to address its domestic bioproliferation dangers.
The Soviet Legacy
At the time of the Soviet Unions collapse, there were about
1.7 million scientific researchers in the country, and the government
financed 97 percent of the research conducted, with many of the scientists
working in military-related programs.[1]
The exact number of BW scientists remains unknown, but nonproliferation
experts generally agree that Soviet biological weapons facilities
in total employed 60,000-65,000 people.[2]
The Soviet BW complex was separated into three distinct areas, which
helped to conceal research activities; the complex contained some
activities that were clearly prohibited by the Biological Weapons
Convention (BWC), although Western intelligence agencies never could
determine to what extent this was so. The complex included:
multiple Ministry of Defense- controlled facilities, employing
around 15,000 people. These facilities conducted research on some
biological agents, such as Lassa fever, probably deemed too sensitive
for Biopreparat institutes.[3]
the Biopreparat network of facilities that employed roughly
40,000 scientists and workers.[4]
This network included 50 nominally civilian/ commercial facilities
that many believe used a civilian cover to engage in
BW activities. The Defense Ministry was in fact the main customer
for Biopreparats work.
six agricultural laboratories, which employed about 10,000
people. Work at these facilities focused on developing pathogens
related to plants and animals.
Stopping the proliferation of biological weapons expertise from the
former Soviet states is complicated by the difficulty in pinpointing
key experts, particularly those with the knowledge to make a key contribution
to a biological weapons program. Recent figures have suggested that
there are anywhere from 5,000 to 10,000 former Soviet biological weapons
scientists with weapons-relevant skills. Ken Alibek, who was deputy
director of Biopreparat immediately before the collapse of the Soviet
Union and who later defected to the United States, has publicly stated
that roughly 100 scientists have the expertise to create a biological
weapon from beginning to end. Some experts have offered higher figures.
Glenn Schweitzer, the International Science and Technology Centers
first executive director, stated that about 25,000 of those formerly
engaged in the Soviet biological weapons complex represented a real
proliferation risk.[5]
Threat Reduction Responses
In April 1992, President Boris Yeltsin formally announced that Russia
would adhere to the provisions of the BWC and that all offensive work
on biological weapons would end immediately. This opened the door
to cooperation between the former Soviet facilities and the United
States under the newly created cooperative threat reduction (CTR)
agenda and its related multilateral institutions.
The U.S. Departments of State, Defense, and Energy; the European Union
(EU); and joint efforts between the United States and other wealthy
nations all currently fund threat reduction programs (see sidebars).
During the past decade, important progress has been made on eliminating
or converting infrastructure in the BW complex. In addition, some
Biopreparat workers have been redirected to peaceful activities. Access
to these facilities also has improved over time as mutual suspicion
has been replaced by partnership. By 2000 the United States had gained
access to approximately 30 of the 50 nonmilitary institutes formerly
associated with Biopreparat,[6]
and a number of these laboratories had begun working on commercial
biotechnology and pharmaceutical projects. This new nonproliferation
cooperation, however, has not extended to allow access to several
key biological facilities controlled by the Defense Ministry.
Standoff on Defense Ministry Facilities
Yeltsins announcement had raised hopes that the Russian government
and military would be more transparent with regard to the military-related
facilities. Yet despite pressing for more than a decade, the United
States and allied nations have failed to gain access to or significant
information about the Defense Ministry-controlled biological facilities.
Most experts agree that there are currently four biological weapons
facilities under the jurisdiction of the Russian Defense Ministry.[7]
The Center of Virology in Sergiev Posad (formerly Zagorsk).
This is the largest military biological facility managed by the
Defense Ministry.
The Center for Military Technical Problems of Anti-Bacteriological
Defense in Ekaterinburg (formerly Sverdlovsk). This facility is
best known for the infamous anthrax outbreak of 1979, which killed
66 people, including some Soviet scientists working at the center.
The Scientific Research Institute of Microbiology in Kirov.
Under the Soviet Union, this facility was active in developing typhus,
Q fever, tularemia, brucellosis, anthrax, and glanders. It also
produced and stockpiled plague. The Kirov-200 Institute in Strizhi
is a related insti- tution. Partial jurisdiction of it was recently
transferred to the Ministry of Education, and it is believed to
be the most commercially oriented of the sites.
The Scientific Research Institute of Military Medicine in
St. Petersburg. This is one of the leading centers for defense against
chemical and bio- logical weapons. It is engaged in vaccine testing,
development of mass immunization and prophy- lactic methods, and
pathogen detection techniques.
U.S. officials have tried to gain access to these facilities on numerous
occasions. Beginning with the Trilateral Agreement of September 1992,
the United States, together with the United Kingdom, negotiated with
Russia for visits (not inspections) to nonmilitary biological
sites. Subsequent negotiations for access to military facilities,
commonly known as the Rules of the Road, took place sporadically from
1994 to 1996 with little result.
Although the issue of access to the Defense Ministry sites remained
part of the nonproliferation dialogue between the United States and
Russia through the end of the decade, this issue assumed a higher
profile after a 2000 General Accounting Office (GAO) report repeatedly
criticized Russias refusal to allow the United States to
inspect its military institutes currently managed by the Ministry
of Defense.[8] Part
of the problem in gaining access to the Defense Ministry facilities,
according to the GAO report, was that the same generals who
directed the Soviet biological weapons program continue to lead the
greatly reduced Russian military defensive biological weapons program.[9]
Some U.S. politicians have independently tried to resolve access issues
with Russia. Senate Foreign Relations Committee Chairman Richard Lugar
(R-Ind.) has been an outspoken critic of the Russian governments
refusal to allow access to the Defense Ministry-run sites. In 2002,
Lugar traveled to Kirov-200, but Russian officials barred him from
entering the facility. For Lugar, the last-minute refusal was a frustrating
reminder of the Russian paradoxical mindset: [T]hey [the Russians]
were interested in getting
pharmaceutical companies to invest
in these facilities. But as I told them, its a non-starter if
investors cant even get inside the place.[10]
In a meeting with Lugar the next day, Russian Defense Minister Sergei
Ivanov provided no explanation for the rebuff.[11]
There are generally three lines of argument that are offered by Russian
officials for excluding foreigners from the Defense Ministry-controlled
sites:
The official Moscow line, continu- ing from the Soviet era,
is that Russia neither has nor had an offensive biological weapons
development or procurement program. The existence of the Defense
Ministry facilities is denied or explained in terms of other
than offensive activities that rep- resent an integral component
of Russian national security.
Russias current biological pathogen research also
is described as en- tirely defensive or peaceful in
nature. Thus, some chief Russian officials argue that access has
been denied to foreigners at the Defense Ministry sites simply because
there is nothing to hide and no reason for them to enter.
A third reason given is that the United States refuses to
accept reci- procity. Some Russian officials insist that, in return
for allowing access to Russian military sites, they be allowed to
visit similar U.S. military facilities. The United States has opposed
this, and it has fed Russian concerns about the true intent and
scope of the U.S. biodefense program.
As a result of the Russian resistance on this issue, the U.S. Congress
has acted to limit the expenditure of threat reduction funds at facilities
that do not allow site access to U.S. agencies. This stance is intended
to ensure that no offensive biological weapons research is being conducted
at facilities receiving U.S. funds and also to increase the pressure
to resolve this access standoff, but it also perpetuates obvious security
concerns.
Possible Solutions
Both the United States and Russia have a mutual interest in finding
agreement on access to the Defense Ministry facilities because each
recognizes the magnitude of the global threat posed by the proliferation
of biological weapons, technology, and expertise. The reorganization
of the Russian government this spring following President Vladimir
Putins re-election and the increasing focus by wealthy and European
nations on reducing the biological weapons threat could create new
opportunities for negotiation on the subject. Bringing the parties
to the negotiating table, however, most likely will require high-level
political involvement, which so far has been lacking.
As a starting point, the United States and Russia could agree to a
confidential exchange of updated information about former and current
(defensively oriented) military facilities. Particular attention should
be directed to the existence of any genetically altered pathogens
that are resistant to current vaccines. The implications of an accidental
release of such a pathogen should transcend rigid adherence to national
security secrecy.
This voluntary exchange of information could begin to establish a
level of trust.
It would then be important to decide whether discussions of access
to the Defense Ministry-run facilities should be reopened. If discussions
were to begin, they could focus on biosafety and biosecurity and the
principles of trust and transparency. An important issue would be
the level of intrusiveness that is acceptable and required for site
visits and how to incorporate degrees of flexibility into the process.
Another consideration is whether to keep the discussions entirely
as a bilateral U.S.-Russian matter or whether the inclusion of other
parties, such as the United Kingdom or other EU nations, NATO, or
perhaps even the United Nations, could help to facilitate the process.
Governments can look to the ongoing collaboration with Russia in other
sensitive nonproliferation areas, especially in the nuclear field,
as a guide for resolving transparency issues at the Defense Ministry-run
facilities. Obtaining access to nuclear cities and facilities was
a long and gradual process during which many obstacles had to be overcome,
and cooperation in this sphere still is far from perfect. Nevertheless,
ways were found to overcome sensitivities and mistrust and to cooperate
effectively in this area, with benefits accruing to all sides. With
renewed diplomatic commitment, both sides could reconcile past differences
and agree to some form of access to the Defense Ministry-run facilities.
Expanding the Effectiveness of Bio-Threat Reduction
Besides solving the problem of Defense Ministry facility access, there
are many additional actions that could be taken at nonmilitary facilities
to expand and improve such threat reduction activities. Increased
funding could be readily absorbed in some key areas such as scientist
re-employment and product commercialization. In fact, a number of
assistance proposals have been approved but await funding.
There also could be better integration between the efforts that target
the elimination of infrastructure and those that focus on scientist
and worker redirection. For example, the biological weapons production
capacity at the Stepnogorsk plant in Kazakhstan was eliminated by
a U.S. program, but this action left many scientists without work.
As similar infrastructure elimination is planned in other former Soviet
states, it would be wise to carry out advance planning for worker
re-employment in order to yield a more substantial and long-lasting
nonproliferation benefit. If the Defense Ministry facility access
problems can be solved, then even greater acceleration of the scope
and funding for bio-threat reduction programs would be in order.
In order to develop a more comprehensive and cooperative strategy
for addressing the dangers posed by unsecured biological pathogens,
the West, Russia, and former Soviet states need to begin working on
the following additional key elements of the program.
Improving Transparency
Although gaining access to Russian military facilities is essential,
there also is a need for greater access to Russian private-sector
biological research facilities. As the biotechnology boom has spread
across Russia and the former Soviet states, many biological institutes
have been privatized. Given the many problems with transparency in
Russia and the sensitive and competitive nature of biotechnology research
and commercialization, concerns naturally arise about the adequate
monitoring of the activities at these private facilities. It is necessary
to guarantee a level of proprietary protection and confidentiality
in order for companies to be competitive, but the international community
must be assured that private owners of these facilities have not bought
them to pursue dangerous ends.
Expanding the Research Agenda
New opportunities for biological weapons scientists need to be identified
and funded. Much of the focus has been on employing scientists on
biodefense projects, but there is also a need to focus even greater
attention on the development and commercialization of affordable pharmaceuticals
and research aimed at solving global health problems. Pharmaceuticals
from the former Soviet states perhaps will not be competitive in the
West, but they could serve needs in Russia, China, and other nations.
Another valuable opportunity might be in employing Russian biological
experts and facilities in the UNs efforts to stem the mushrooming
global HIV/AIDS epidemic. Finally, former weapons scientists could
be drafted to participate in the improvement of public health in their
local areas. Disease surveillance and health-care planning are crucial
elements in minimizing the potential impact of bioterrorism, and this
is one area where the local facilities could be better integrated
with global networks such as the World Health Organization.
Creating an EU Initiative
Expanded EU involvement would also be a welcome supplement to current
efforts. The EU has recognized the increasing danger posed by bioterrorism
and the need to expand threat reduction initiatives to deal with it.[12]
Indeed, both the United Kingdom and France have indicated that this
will be an area of intensified focus. The EU nations could concentrate
on expanding biosafety and biosecurity upgrades and contributing to
the creation of biotechnological parks at critical sites. For example,
environmental monitoring labs have been established at Stepnogorsk
and Kirov with help from the United States, but many proposals and
project ideas for these centers remain unfunded, including analyses
that could contribute to environmental pollution mitigation and food
safety improvement. Also, EU governments and industries could investigate
the potential benefits of greater cooperation on civilian biotechnology.
Insuring Best Practices
There is a need to support training and education in biosecurity and
biosafety best practices and to reinforce ethical norms and codes
of conduct as a tool to combat the misapplication of biology by scientists.
This is a problem faced by many nations, not just Russia and the former
Soviet states. Improving the quality of biosafety and biosecurity
measures at key facilities will also help to improve their ability
to market their capabilities and products to Western commercial partners
as well as deepen cooperation, transparency, and trust, potentially
leading to progress in other areas.
Conclusion
The world is facing an increasingly challenging battle against potential
bioterrorism. Advances in biotechnology are occurring rapidly, and
the traditional arms control methods of controlling biological weapons
are increasingly inadequate to address the modern-day challenges.
The global community, and in particular the wealthy nations involved
in the G-8 Global Partnership Against the Spread of Weapons and Materials
of Mass Destruction, need to develop new cooperative, synergistic,
and effective strategies that can mitigate the bioterrorism danger.
The recent statement from the G-8 summit at Sea Island, Georgia, underscored
the unique and grave threats posed by bioterrorism but
contained no new funding pledges or programs. Rather, it focused primarily
on the effective implementation of the prohibitions contained in the
BWC as the primary defense against biological weapons. This narrow
response is insufficient.
Effectively addressing the proliferation danger from biological weapons
will require targeting new funding on underfinanced areas, including
rapidly increasing security and safety at all biological facilities,
expanding research opportunities, and creating new commercial initiatives.
The place to begin is in Russia and the former Soviet states, where
the largest problems exist and where existing CTR mechanisms allow
for rapid action. Yet, the effort cannot stop there. It must be extended
globally to prevent any dangerous biological pathogens from falling
into the hands of terrorists.
ENDNOTES
1. Elena Kokurina, Obschaya Gazeta, (November
1-7, 2001), p. 6. This article was translated by the U.S. Civilian
Research and Development Foundation on November 13, 2001.
2. The Center for Strategic and International
Studies and the Congressional Research Service place the number at
60,000, and the Henry L. Stimson Center, citing an annonymous government
official, puts the number at 65,000.
3. Jonathan B. Tucker, Biological Weapons
in the Former Soviet Union: An Interview With Dr. Kenneth Alibek,
The Nonproliferation Review, Spring/Summer 1999, p. 4.
4. Amy Smithson, Toxic Archipelago: Preventing
Proliferation From the Former Soviet Chemical and Biological Weapons
Complexes (Washington, DC: Henry L. Stimson Center, 1999), p. 10.
5. Nuclear Threat Initiative, Russia: International
Science and Technology Center (ISTC).
6. U.S. General Accounting Office (GAO), Biological
Weapons: Efforts to Reduce Former Soviet Threat Offers Benefits, Poses
New Risks, GAO/NSIAD-00-138, April 2000, p. 6.
7. The precise number and identity of the Defense
Ministry-controlled facilities has varied in recent years. In
information submitted to the UN in 1987, the Soviet Union declared
five institutes under Ministry of Defense control: Leningrad (now
St. Petersburg), Kirov, Sverdlovsk (now Yekaterineberg), Zagorsk (now
Sergiev Posad), and Aralsk [this facility is actually located near
the Vozrozdheniya Island test site, which has been decontaminated].
Russias 1992 declaration referred to Kirov, Sverdlovsk, and
Zagosrk, as well as to the sites Obolensk, Chekhov, Leningrad,
and the Vozrozdheniya Island test site. Graham S. Pearson et al.,
Biological Weapons Proliferation: Reasons for Concern, Courses
of Action, Henry L. Stimson Center Report No. 18, January 1998,
p. 29.
8. GAO, Biological Weapons, pp. 3-4.
9. Ibid, p. 16.
10. Ibid.
11 . Joby Warrick, Russia Denies U.S.
Access on Bioweapons, The Washington Post, September
8, 2002, p. A25.
12. There are two significant EU documents that
address bioterrorism and the importance of threat reduction: Presidency
Conclusion, Annex II, Declaration on Non Proliferation of Weapons
of Mass Destruction, Thessaloniki, June 19-20, 2003; Javier Solana,
A Secure Europe in a Better World, European Council, Thessaloniki,
June 20, 2003.
|
Funding for Bio-Threat Reduction
The United States, the European Union, and other global actors
have initiated a variety of efforts to eliminate the residue
of Soviet biological weapons programs.
U.S. Programs
Three U.S. agencies have programs to reduce biological weapons
proliferation from Russia and the former Soviet states:
Defense Department
The Department of Defense, through its Biological Weapons Proliferation
Prevention Program, has four major project areas devoted to
the reduction of bio-threats.
The Cooperative Biological Research program funds
civilian research projects at eight bio-institutes in the
former Soviet states.
The Bio-Safety/Bio-Security program has sponsored
training courses for scientists in proper animal care and
animal testing procedures and installed physical security
systems in Russian, Kazakh, and Uzbek institutes.
The Infrastructure Elimination pro- gram has removed
weapons-related equipment from three biological weapons production
buildings at the former anthrax production facility in Stepnogorsk,
Kazakhstan, and elimi- nated live anthrax material on Vozrozhdeniye
Island in Uzbekistan by either destroying it or evacuating
it to other facilities.
The newly established Threat Assessment/Disease Response
program is designed to upgrade the diagnostic methods of outdated
disease monitoring facilities in Kazakhstan, Uz- bekistan,
and Georgia and to relocate pathogen libraries from these
Soviet- established tracking stations to central reference
laboratories.
Total funding for these four efforts is currently about $55
million per year. In its fiscal year 2005 budget request (for
the budget year beginning Oct. 1), the Pentagon proposed substantially
cutting cooperative research funding and more than doubling
funds for biosecurity and biosafety.
|
U.S. Funding for Bio-Reduction in the Former Soviet Union,
by Deapartment (in millions of dollars)[1]
| FISCAL YEAR |
2000
|
2001
|
2002
|
2003
|
2004
|
2005
(Requested)
|
|
Energy
IPP funding for bio-related projects
|
7-8
|
7-8
|
7-8
|
7-8
|
7-8
|
7-8
|
Defense
DTRA, BWPP |
14
|
12
|
17
|
55
|
54
|
55
|
State[2]
BII, Bio-Chem Redirect |
19
|
16
|
45
|
20
|
24
|
20
|
1.
Funding for the Pentagons biological weapons threat
reduction activities is roughly $55 million per year.
The Department of States Bio Industry Initiative
(BII) received a one-time appropriation of $30 million
in fiscal year 2002 that is being spent over multiple
years; it requested an additional $3 million in the fiscal
year 2005 budget request. The State Departments
Bio-Chem Redirect program is about $18 million per year.
Budget documents indicate that $13 of the $17 million
requested for Bio-Chem Redirect for fiscal year 2005 will
be spent on bio-related projects. Bio-Chem Redirect also
provided some funding for BII in fiscal year 2003 and
2004 ($2 and $4 million, respectively). The Department
of Energys Initiatives for Proliferation Prevention
(IPP) program allocates roughly $7-8 million to bio-related
programs. The United States also contributes roughly $30
million per year to the science centers in Moscow and
Kiev, which spend about 28 percent (approximately $8 million)
of their annual funds on biological and related projects.
Based on these figures, the authors estimate U.S. funding
at $90-100 million per year.
2.
This line combines funding for both the Bio-Chem Redirect
and BII programs. Beyond its $30 million appropriation
in FY02, and its $3 million request for FY05, BII also
has received support from Bio-Chem Redirect in FY03 ($2
million) and FY04 ($4 million).
|
State Department
The State Department leads two major initiatives focused on
the redirection of biological weapons expertise to civilian
purposes.
The Bio-Industry Initiative (BII) pro- gram was established
in 2002 with an initial appropriation of $30 million; it is
now seeking $3 million in funding in fiscal year 2005. The
goal of the BII effort is to reconfigure former Soviet bio-production
facilities to commercial uses and engage former weapons scientists
in civilian research projects, such as the development of
drugs and vaccines. To date, it has provided mar- ket research
assistance and training in Good Management/Good Laboratory
Practices (GMP/GLP), set up a com- mercial consortium
of biotechnology production facilities, and established a
toxicology testing initiative to improve the quality and pre-clinical
services that can be provided to contract cus- tomers by Russian
biotech institutes.
The Bio-Chem Redirect program is a multi-agency effort,
led and adminis- tered by the State Department, specifi- cally
focused on redirecting biological a chemical weapons scientists.
The funds are provided to the Environ- mental Protection Agency
and the Departments of Health and Human Services and Agriculture.
Key accom- plishments of the program include the establishment
of environmental mon- itoring laboratories at the former an-
thrax production facility at Stepnogo- rsk in Kazakhstan and
at Kirov in Russia.
Energy Department
The Department of Energys Initiatives for Proliferation
Prevention (IPP) program has provided more than $30 million
to date to re-employ biological experts in commercially oriented
projects. It currently spends approximately $7-8 million per
year on biological projects and, like the State and Defense
Departments programs, has more project proposals in hand than
it is able to fund. One of the Energy Departments key
strategies is to build infrastructure and capacities in former
Soviet facilities in order to allow them to graduate
and become self-sustaining commercial enterprises.
Multilateral Efforts
Science Centers
Multilateral contributions to biological weapons threat reduction
have been primarily channeled through the International Science
and Technology Center (ISTC) in Moscow and the Science and Technology
Center of Ukraine (STCU) in Kiev, both of which provide funding
for peaceful activities for former weapons scientists.
Through the end of 2003, the ISTC had provided roughly $130
million in funding for more than 700 regular and partner projects
in biotechnology and life sciences. Such projects in recent
years have been an increasing focus of the centers work.
Similarly, the STCU has spent more than $7 million to date on
biotechnology and related medical projects.
In addition to the U.S. direct financial contribution to the
ISTC each year (on the order of $30 million), many U.S. government
agencies also funnel parts of their funding for biological projects
through the ISTCs Partnership Program. U.S. agencies typically
fund projects that correspond to their own expertise and research
priorities. For example, in its partnerships with former Soviet
institutions, the Pentagon has supported research applicable
to the biodefense field. Overall, U.S. government agencies have
funded more than $30 million in biotechnology and life sciences
partner projects under the ISTC.
G-8 Global Partnership
With the creation of the Group of Eight (G-8) Global Partnership
in 2002 at the Kananaskis summit in Canada, eight of the worlds
wealthiest countries pledged to provide up to $20 billion over
the next decade for weapons of mass destruction threat reduction
and nonproliferation programs (mainly in Russia). The United
States is expected to contribute $10 billion over this period
while the remainder would be provided by the other G-8 nations
and countries that join the Global Partnership.
Few of these pledged funds have yet been spent to contain the
spread of biological weapons. According to official reports
of a G-8 meeting in March 2004, the major projects were funded
by the United Kingdom ($405,000) and Sweden ($130,000). However,
the G-8 is expected to mount an intensified effort to reduce
the threat posed by biological weapons. Canada, for example,
recently pledged in joining the ISTC that a significant portion
of its $13 million contribution would go toward such efforts.
Likewise, British officials have pledged to increase funds.
At the recent G-8 summit, France indicated that it would initiate
a € 5 million program for biosecurity improvements at Russian
laboratories.
European Union Programs
The European Union (EU) primarily has funded efforts to reduce
the threat of biological weapons though contributions to the
ISTC and the STCU. The EU allocation through 2005 was €125
million for the peaceful employment of former weapons scientists.
The EU also provides funding for cooperative threat reduction-like
activities through two additional programs, the EU Joint Action
and TACIS (Technical Assistance to the CIS). At this point,
none of this funding appears to have been directed toward reducing
biological weapons threats, but EU officials have indicated
that bio-threat reduction may be a higher priority when the
new budget cycle begins in 2007.
In addition, INTAS, an independent international association,
is promoting scientific cooperation between researchers in former
Soviet republics and those in EU member states and other countries
such as Israel and Turkey. All told, INTAS has funded more than
300 biotechnology and life science projects. Additionally, the
NATO-Russia Joint Scientific and Technological Cooperation program
has provided grant support to Russian scientists in plant biotechnology,
as well as plasma physics and forecast and prevention of catastrophes.
Depending on the size of the project team, funding for the collaborative
linkage grants usually falls between $5,000 and $20,000.
|
Kenneth Luongo is executive director of the Russian-American
Nuclear Security Advisory Council (RANSAC). Derek Averre is senior
research fellow at the Centre for Russian and East European Studies
at the University of Birmingham, U.K. Raphael Della Ratta is director
of the Weapon Scientist Redirection Project at RANSAC. Maurizio Martellini
is secretary-general of the Landau Network Centro-Volta, Como, Italy.
The article is based in part on the findings of a meeting organized
by the authors in Como, Italy, in November 2003 on the future of bio-threat
reduction.
|